{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.5","upperLimit":"12","value":"9.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"Time to Treatment Failure: Time from administration of the initial dose of axitinib until study discontinuation for any reason (e.g., disease progression, toxicity, death, withdrawal of consent).","dispersionType":"95% Confidence Interval","groups":[{"description":"The investigational drug used in this study is axitinib, and is available as tablets.","id":"OG000","title":"Axitinib Administration"}],"paramType":"MEDIAN","populationDescription":"All participants.","reportingStatus":"POSTED","timeFrame":"12 Months","title":"Time to Treatment Failure","type":"SECONDARY","unitOfMeasure":"months"}